Who qualifies for a GLP-1 prescription?
FDA-approved indications determine who a clinician can prescribe a GLP-1 medication to "on-label." Going outside these indications is "off-label" and is the prescriber's clinical judgment — legal but not always covered by insurance.
For chronic weight management (Wegovy, Zepbound, Saxenda)
FDA labels generally require:
- BMI ≥30 kg/m², OR
- BMI ≥27 kg/m² with at least one weight-related comorbidity — for example: hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, or polycystic ovary syndrome.
Wegovy was also approved (2022) for adolescents 12 and older at the 95th BMI percentile for age and sex. Wegovy and Zepbound have additional indications for cardiovascular risk reduction (Wegovy) and obstructive sleep apnea in obesity (Zepbound) that broaden the on-label population.
For type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Byetta, Bydureon)
A documented diagnosis of type 2 diabetes is required. Most prescribers will want to see HbA1c data and, depending on the agent, may consider GLP-1 receptor agonists at various points in the treatment ladder — sometimes earlier in patients with established cardiovascular disease, given the cardiovascular outcome data.
Off-label use for weight loss with Ozempic or Mounjaro
Ozempic and Mounjaro are FDA-approved for diabetes, not weight management. Prescribing them for weight loss alone is off-label and is at the clinician's discretion. Many clinicians prefer to prescribe Wegovy (weight indication for semaglutide) or Zepbound (weight indication for tirzepatide) when weight management is the goal, both for label alignment and for predictable insurance coverage.
Contraindications
Regardless of indication, GLP-1 receptor agonists are contraindicated in:
- Personal or family history of medullary thyroid carcinoma (MTC).
- Multiple endocrine neoplasia syndrome type 2 (MEN-2).
- Known hypersensitivity to the active ingredient or excipients.
- Pregnancy or planned pregnancy (semaglutide should be discontinued at least two months before).
Caution applies for: history of pancreatitis, severe gastroparesis, active gallbladder disease, advanced kidney disease, and several other conditions. A clinical evaluation determines whether GLP-1 is appropriate for the individual.
Find out in a few minutes whether you qualify
A licensed clinician can review your health history and tell you whether a GLP-1 medication is clinically appropriate for you.
Check Your Eligibility →Sponsored link. We earn a commission when you sign up. Medical eligibility determined by licensed providers. Disclosure
Three pathways to a GLP-1 prescription
| Pathway | Time to first prescription | Typical cost | Insurance use | Best for |
|---|---|---|---|---|
| Primary care physician (in-person) | Weeks (appointment availability) | Office visit copay + Rx cost (varies by insurance) | Most likely to use insurance | Patients with established primary care relationship and good insurance coverage |
| Telehealth platform (video visit) | 24-72 hours from intake | Self-pay $150-$500/month bundled; some platforms also handle brand-name through insurance | Often self-pay; some platforms work with insurance for brand-name | Patients prioritizing speed, convenience, or compounded options |
| Medical weight loss clinic | 1-2 weeks | Variable — often packaged with lifestyle counseling | Some accept insurance; many are self-pay | Patients wanting structured weight management with lifestyle support |
Pathway 1: Primary care physician
The traditional pathway. Schedule with your PCP, discuss your weight history, comorbidities, and goals. Your physician may order labs (HbA1c, lipid panel, comprehensive metabolic panel, thyroid screen) and, if appropriate, write a prescription for Wegovy, Zepbound, Ozempic, or another GLP-1 medication.
Pros
- Continuity of care with a clinician who knows your full history.
- Best chance of using commercial insurance, including processing prior authorization.
- Integrated lab and follow-up infrastructure.
Cons
- Appointment wait times can be weeks to months.
- Some PCPs are less familiar with the GLP-1 prescribing landscape and may not have an established workflow for weight-management prescriptions.
- Compounded options usually not available through this pathway.
- Insurance prior authorization can extend time to first dose by 1-4 weeks even after the prescription is written.
Tips
- Come to the appointment with: weight history, BMI, list of comorbidities, current medications, prior weight loss attempts.
- If you have commercial insurance, check your formulary in advance to see whether Wegovy, Zepbound, or another GLP-1 is covered and what step therapy may be required.
- Ask whether your physician handles prior authorization in-office or refers to a specialist.
Pathway 2: Telehealth platform
The fastest-growing pathway. You complete a detailed online intake, have a synchronous video visit with a clinician licensed in your state, and receive a prescription that ships directly to you. Most telehealth platforms work with both brand-name and compounded GLP-1 options.
The typical flow
- Online intake (15-30 minutes). Detailed health history, weight history, comorbidities, current medications, allergies, contraindications. Some platforms also ask about prior GLP-1 use.
- Synchronous video visit (15-30 minutes). Required for legal prescribing in most states. The clinician reviews your history, asks follow-up questions, and determines clinical eligibility.
- Labs, where needed. Some platforms require baseline labs; others proceed based on history. The standard of care generally favors basic labs at initiation.
- Prescription decision (24-72 hours typical). If approved, prescription is sent to a partnered pharmacy.
- Medication ships (3-7 business days typical). Cold-chain shipping for injectable products.
- Ongoing care. Most programs include scheduled or as-needed follow-up to manage titration and side effects.
Pros
- Speed: from intake to medication in roughly one week.
- Convenience: no in-person visit, evening and weekend availability.
- Compounded options often available where legally appropriate.
- Transparent self-pay pricing.
Cons
- Less likely to use commercial insurance (some platforms support both).
- Care relationship is medication-focused; not a substitute for a primary care physician.
- Quality varies — see the next section on evaluating a platform.
How to evaluate a telehealth platform
- Synchronous video visit, not just a questionnaire. A real video evaluation with a licensed clinician is the standard. Asynchronous-only "prescribing" via questionnaire is restricted in many states and creates a less robust clinical relationship.
- Licensed clinicians in your state. A physician, nurse practitioner, or physician assistant must hold a license in the state where you reside.
- Transparent pharmacy partner. The platform should be willing to identify the pharmacy that will fill your prescription, especially for compounded options.
- Quality controls on compounded products. USP <797> compliance, third-party potency and sterility testing.
- Side effect management protocols. Clear process for reaching a clinician when problems arise.
- Reasonable cancellation policy. Avoid platforms that lock you into multi-month plans with no exit if the medication does not work for you.
Start a telehealth evaluation
Online intake, video evaluation with a licensed clinician, and shipped medication if you qualify.
Start My Online Visit →Sponsored link. We earn a commission when you sign up. Medical eligibility determined by licensed providers. Disclosure
Pathway 3: Medical weight loss clinic
Specialized clinics that combine medical prescribing with lifestyle counseling (registered dietitians, exercise physiologists, sometimes behavioral health). Some are integrated with health systems; others are independent practices.
Pros
- Structured lifestyle and behavioral support to complement medication.
- Clinician expertise in obesity medicine.
- Often more flexible scheduling than primary care.
Cons
- Often partially or fully self-pay; insurance coverage of clinic services varies.
- Quality varies dramatically — some are evidence-based obesity medicine practices, others are weight-loss-themed wellness clinics with limited rigor.
- Geographic availability is uneven.
How to evaluate
- Look for clinicians who are American Board of Obesity Medicine (ABOM) certified.
- Ask about their relationship with primary care — a good obesity medicine practice coordinates with your PCP, not replaces them.
- Be cautious of clinics that require expensive long-term contracts before any clinical evaluation.
Insurance versus self-pay
Insurance coverage of GLP-1 medications varies enormously by:
- Indication: diabetes indications (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Byetta, Bydureon) are commonly covered by commercial insurance. Weight-management indications (Wegovy, Zepbound, Saxenda) are covered by some commercial plans, many self-insured employers, but generally not Medicare Part D (a 2003 federal law excludes weight-loss drugs from Part D; reform is under discussion).
- Plan formulary: within a given carrier, plans differ.
- Prior authorization requirements: often documented BMI, comorbidities, prior weight loss attempts.
- Step therapy: some plans require trying older or cheaper agents first.
Self-pay options for brand-name
- Manufacturer savings cards (NovoCare for Novo Nordisk products, LillyDirect for Eli Lilly products) can reduce out-of-pocket cost for eligible commercially insured patients.
- Direct-to-patient programs: Eli Lilly's LillyDirect sells some Zepbound vial strengths for self-pay at roughly $349-$499/month as of 2026.
Self-pay options for compounded
- Compounded semaglutide: typically $150-$400/month.
- Compounded tirzepatide: typically $200-$500/month.
- Generally not covered by insurance (not an FDA-approved drug product).
State telemedicine considerations
Telemedicine prescribing rules vary by state. As of 2026:
- All US states allow synchronous video-visit prescribing for non-controlled medications when the clinician is licensed in the patient's state.
- Asynchronous-only prescribing (questionnaire without video) is restricted or prohibited in many states.
- Some states have moved to restrict compounded GLP-1 prescriptions independent of FDA shortage status.
- Establishing the clinician-patient relationship is the foundational requirement; this is generally accomplished by a synchronous video visit.
Telehealth platforms operate within these rules, which is why some are available in some states but not others.
Checklist before you start
- BMI and weight history documented.
- Comorbidities list (hypertension, dyslipidemia, T2D, sleep apnea, etc.).
- Current medications and supplements list.
- Allergies.
- Thyroid history (personal and family).
- Pancreatitis or gallbladder history.
- Pregnancy plans (if applicable).
- Insurance information, if you intend to use it.
- Recent lab results, if available.
Bottom line
You can get prescribed a GLP-1 medication through your primary care physician, a telehealth platform, or a medical weight management clinic. The right pathway depends on your priorities — insurance use, speed, integration with primary care, structured lifestyle support, compounded versus brand-name. The common thread across all three: a licensed clinician evaluates you, confirms eligibility, screens for contraindications, and writes a prescription.
For most patients without a primary care relationship dedicated to weight management, telehealth is the fastest and most predictable route to a first prescription — usually one week from intake to medication.
Ready to start?
A licensed clinician via telehealth can evaluate your eligibility for FDA-approved or legally compounded GLP-1 medications.
Check Your Eligibility →Sponsored link. We earn a commission when you sign up. Medical eligibility determined by licensed providers. Disclosure